Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2014. The report details a specific share repurchase transaction executed on May 21, 2014, pursuant to shareholder authority granted at the Annual General Meeting on May 7, 2014.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure and share repurchase activity.
- Shares Purchased: 430,900 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,633.00 pence per share; lowest price paid was 1,617.50 pence per share.
- Treasury Holdings (Settled): 491,866,812 shares (9.19% of total issued share capital).
- Treasury Holdings (Including Unsettled): 493,444,212 shares (10.16% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,858,661,690 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 430,900 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.16% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Points
- Verify the total number of shares held in Treasury (491,866,812 settled) against the company's latest capitalization table.
- Confirm the denominator for voting rights calculations is 4,858,661,690 shares (excluding Treasury) as stated for FCA notification purposes.
- Review the price paid (1,617.50 to 1,633.00 pence) against the market price on May 21, 2014, to assess execution efficiency.